GammaCan Announces 2005 EULAR Prize Awarded to Dr. Yehuda Shoenfeld; Chief Scientific Officer and Inventor of Company's IVIg Therapy Makes Significant Strides in Potential Treatment Of Auto-Immune Disease - Anitphospholipid Syndrome.

GIVAT SHMUEL, Israel -- GammaCan International, Inc. (OTC BB:GCAN), a developer of immunotherapies for cancer and other serious conditions, today announced that the Company's Chief Scientific Officer, Dr. Yehuda Shoenfeld, along with two colleagues, was awarded the 2005 EULAR (European Union Congress of Rheumatology) Prize for his research in Antiphospholipid Syndrome (APS) - a life-threatening auto-immune disease. Dr. Yehuda Shoenfeld's published work in this field (Intravenous Immunoglobulin Therapy of Antiphospholid Syndrome, Rheumatology 2000; 39:421-426) has paved the way for the use of IVIg for the treatment of patients suffering APS.

Dr. Shoenfeld's research has provided the basis for Gammacan's IVIg anti-cancer immunotherapy and the Company is hopeful that the Phase IIA clinical trials currently in progress will further substantiate his published research in animals that IVIg is effective in the treatment of metastatic cancer.

Dr. Shoenfeld is the Incumbent of the Laura-Schwarz-Kipp Chair for the Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel Aviv University. He is a world-renowned author in the field of immunology and has been published in numerous peer reviewed journals.

About GammaCan

GammaCan is focusing on the commercialization of a revolutionary anti-cancer immunotherapy that the Company believes will be proven to be effective in reducing the metastastic spread of a wide range of cancers. GammaCan's proposed treatment is based in IVIg, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. It works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. Approximately twenty companies produce IVIg, and annual worldwide sales are currently in excess of 50 metric tons with an estimated value in excess of 1.5 billion USD. IVIg is commonly used to treat certain autoimmune diseases and blood disorders and to replace the antibodies in people who are unable to produce them. For more information about Gammacan visit http://www.gammacan.com or call the company's headquarters in Givat Shmuel, Israel at 972-3-5774475.

Safe Harbor Statement:

Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIg into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early state medical research and development companies filed with the SEC on Edgar.